Impacted by the temporary closure of clinics and the deferral of elective procedures, CZM’s Q3 sales were down 30.2% – ophthalmic devices as well as microsurgery witnessed a decline of similar magnitude. Operational deleverage and continued investments into R&D pressurised the adjusted operating profit further (-84.4%). However, with the gradual resumption of elective procedures, a recovery is expected in Q4 with consumables likely to fare better than equipment. The launch of
06 Aug 2020
Deferral of elective procedures weighs on Q3
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Deferral of elective procedures weighs on Q3
Carl Zeiss Meditec AG (AFX:WBO) | 0 0 1.8% | Mkt Cap: 4,494m
- Published:
06 Aug 2020 -
Author:
Sumit Sayal -
Pages:
3
Impacted by the temporary closure of clinics and the deferral of elective procedures, CZM’s Q3 sales were down 30.2% – ophthalmic devices as well as microsurgery witnessed a decline of similar magnitude. Operational deleverage and continued investments into R&D pressurised the adjusted operating profit further (-84.4%). However, with the gradual resumption of elective procedures, a recovery is expected in Q4 with consumables likely to fare better than equipment. The launch of